Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2011 (2011), Article ID 147689, 11 pages
http://dx.doi.org/10.4061/2011/147689
Review Article

The Facial Skeleton in Patients with Osteoporosis: A Field for Disease Signs and Treatment Complications

1Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
2Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
3Department of Endocrinology, 424 Military Hospital, Thessaloniki 56429, Greece

Received 27 November 2010; Revised 31 December 2010; Accepted 15 January 2011

Academic Editor: Joonas Sirola

Copyright © 2011 Athanassios Kyrgidis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Y. Reginster and N. Burlet, “Osteoporosis: a still increasing prevalence,” Bone, vol. 38, no. 2, supplement 1, pp. S4–S9, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. C. Cooper, G. Campion, and L. J. Melton III, “Hip fractures in the elderly: a world-wide projection,” Osteoporosis International, vol. 2, no. 6, pp. 285–289, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. L. J. Melton, E. A. Chrischilles, C. Cooper, A. W. Lane, and B. L. Riggs, “Perspective: how many women have osteoporosis?” Journal of Bone and Mineral Research, vol. 7, no. 9, pp. 1005–1010, 1992. View at Google Scholar · View at Scopus
  4. A. Randell, P. N. Sambrook, T. V. Nguyen et al., “Direct clinical and welfare costs of osteoporotic fractures in elderly men and women,” Osteoporosis International, vol. 5, no. 6, pp. 427–432, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. B. E. Rosengren, H. G. Ahlborg, P. Gärdsell et al., “Bone mineral density and incidence of hip fracture in Swedish urban and rural women 1987–2002,” Acta Orthopaedica, vol. 81, no. 4, pp. 453–459, 2010. View at Publisher · View at Google Scholar · View at PubMed
  6. M. Toumba and N. Skordis, “Osteoporosis syndrome in thalassaemia major: an overview,” Journal of Osteoporosis, vol. 2010, Article ID 537673, 7 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. B. J. Edwards, M. Gounder, J. M. McKoy et al., “Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw,” The Lancet Oncology, vol. 9, no. 12, pp. 1166–1172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. Edwards and C. A. Migliorati, “Osteoporosis and its implications for dental patients,” Journal of the American Dental Association, vol. 139, no. 5, pp. 545–552, 2008. View at Google Scholar · View at Scopus
  9. M. L. Bouxsein and E. Seeman, “Quantifying the material and structural determinants of bone strength,” Best Practice & Research: Clinical Rheumatology, vol. 23, no. 6, pp. 741–753, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. M. Lewiecki and N. E. Lane, “Common mistakes in the clinical use of bone mineral density testing,” Nature Clinical Practice Rheumatology, vol. 4, no. 12, pp. 667–674, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. C. Bauer, C. C. Gluer, J. A. Cauley et al., “Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women: a prospective study,” Archives of Internal Medicine, vol. 157, no. 6, pp. 629–634, 1997. View at Google Scholar · View at Scopus
  12. E. S. Siris, S. K. Brenneman, E. Barrett-Connor et al., “The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA),” Osteoporosis International, vol. 17, no. 4, pp. 565–574, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. E. S. Siris, YA. T. Chen, T. A. Abbott et al., “Bone mineral density thresholds for pharmacological intervention to prevent fractures,” Archives of Internal Medicine, vol. 164, no. 10, pp. 1108–1112, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. P. D. Miller, E. S. Siris, E. Barrett-Connor et al., “Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the national osteoporosis risk assessment,” Journal of Bone and Mineral Research, vol. 17, no. 12, pp. 2222–2230, 2002. View at Google Scholar · View at Scopus
  15. “Prevention and management of osteoporosis,” WHO Technical Report Series 921, World Health Organization, Geneva, Switzerland, 2003.
  16. S. R. Cummings, M. C. Nevitt, W. S. Browner et al., “Risk factors for hip fracture in white women,” The New England Journal of Medicine, vol. 332, no. 12, pp. 767–773, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. D. R. Johnson, “Introductory Anatomy: Bones,” Faculty of Biological Sciences, University of Leeds, http://www.leeds.ac.uk/chb/lectures/anatomy3.html.
  18. J. M. Richman, M. Buchtová, and J. C. Boughner, “Comparative ontogeny and phylogeny of the upper jaw skeleton in amniotes,” Developmental Dynamics, vol. 235, no. 5, pp. 1230–1243, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. B. K. Hall, “The induction of neural crest-derived cartilage and bone by embryonic epithelia: an analysis of the mode of action of an epithelial-mesenchymal interaction,” Journal of Embryology and Experimental Morphology, vol. 64, pp. 305–320, 1981. View at Google Scholar · View at Scopus
  20. L. A. Opperman, “Cranial sutures as intramembranous bone growth sites,” Developmental Dynamics, vol. 219, no. 4, pp. 472–485, 2000. View at Google Scholar · View at Scopus
  21. M. J. Ravosa, C. J. Vinyard, M. Gagnon, and S. A. Islam, “Evolution of anthropoid jaw loading and kinematic patterns,” American Journal of Physical Anthropology, vol. 112, no. 4, pp. 493–516, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. U. I. Chung, H. Kawaguchi, T. Takato, and K. Nakamura, “Distinct osteogenic mechanisms of bones of distinct origins,” Journal of Orthopaedic Science, vol. 9, no. 4, pp. 410–414, 2004. View at Google Scholar · View at Scopus
  23. B. F. Eames, L. De la Fuente, and J. A. Helms, “Molecular ontogeny of the skeleton,” Birth Defects Research Part C, vol. 69, no. 2, pp. 93–101, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. E. Zins, C.-J. Langevin, and S. Nasir, “Controversies in skull reconstruction,” Journal of Craniofacial Surgery, vol. 21, no. 6, pp. 1755–1760, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. R. I. Henkin, M. D. Lifschitz, and A. L. Larson, “Hearing loss in patients with osteoporosis and Paget's disease of bone,” American Journal of the Medical Sciences, vol. 263, no. 5, pp. 383–392, 1972. View at Google Scholar · View at Scopus
  26. A. D. Anastasilakis, K. A. Toulis, S. A. Polyzos, and E. Terpos, “RANKL inhibition for the management of patients with benign metabolic bone disorders,” Expert Opinion on Investigational Drugs, vol. 18, no. 8, pp. 1085–1102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. D. Anastasilakis, K. A. Toulis, D. G. Goulis et al., “Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis,” Hormone and Metabolic Research, vol. 41, no. 10, pp. 721–729, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. K. C. Horner, Y. Cazals, R. Guieu, M. Lenoir, and N. Sauze, “Experimental estrogen-induced hyperprolactinemia results in bone-related hearing loss in the guinea pig,” American Journal of Physiology, vol. 293, no. 5, pp. E1224–E1232, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. D. Seriwatanachai, N. Charoenphandhu, T. Suthiphongchai, and N. Krishnamra, “Prolactin decreases the expression ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin in human fetal osteoblast cells,” Cell Biology International, vol. 32, no. 9, pp. 1126–1135, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. F. Zehnder, A. G. Kristiansen, J. C. Adams, S. G. Kujawa, S. N. Merchant, and M. J. McKenna, “Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss,” The Laryngoscope, vol. 116, no. 2, pp. 201–206, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. C. Horner, “The effect of sex hormones on bone metabolism of the otic capsule—an overview,” Hearing Research, vol. 252, no. 1-2, pp. 56–60, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. D. Vibert, M. Kompis, and R. Häusler, “Benign paroxysmal positional vertigo in older women may be related to osteoporosis and osteopenia,” Annals of Otology, Rhinology and Laryngology, vol. 112, no. 10, pp. 885–889, 2003. View at Google Scholar · View at Scopus
  33. D. Vibert, A. Sans, M. Kompis et al., “Ultrastructural changes in otoconia of osteoporotic rats,” Audiology and Neurotology, vol. 13, no. 5, pp. 293–301, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. D. Kandelman, P. E. Petersen, and H. Ueda, “Oral health, general health, and quality of life in older people,” Special Care in Dentistry, vol. 28, no. 6, pp. 224–236, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. L. B. Christensen, B. Hede, and P. E. Petersen, “Public dental health care program for persons with disability,” Acta Odontologica Scandinavica, vol. 63, no. 5, pp. 278–283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. P. E. Petersen, “Oral healthcare in people living with cancer,” Oral Oncology, vol. 46, no. 6, pp. 399–400, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. P. E. Petersen, “Global policy for improvement of oral health in the 21st century—implications to oral health research of World Health Assembly 2007, World Health Organization,” Community Dentistry and Oral Epidemiology, vol. 37, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. A. Jablonski, C. L. Munro, M. J. Grap, and R. K. Elswick, “The role of biobehavioral, environmental, and social forces on oral health disparities in frail and functionally dependent nursing home elders,” Biological Research for Nursing, vol. 7, no. 1, pp. 75–82, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. K. R. Phipps, B. K. S. Chan, T. E. Madden et al., “Longitudinal study of bone density and periodontal disease in men,” Journal of Dental Research, vol. 86, no. 11, pp. 1110–1114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. N. C. Geurs, “Osteoporosis and periodontal disease,” Periodontology 2000, vol. 44, no. 1, pp. 29–43, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. E. K. Kaye, “Bone health and oral health,” Journal of the American Dental Association, vol. 138, no. 5, pp. 616–619, 2007. View at Google Scholar
  42. H. Inaba and A. Amano, “Roles of oral bacteria in cardiovascular diseases—from molecular mechanisms to clinical cases: implication of periodontal diseases in development of systemic diseases,” Journal of Pharmacological Sciences, vol. 113, no. 2, pp. 103–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. S. R. P. Orrico, G. Giro, D. Gonçalves, L. Takayama, and R. M. R. Pereira, “Influence of the period after ovariectomy on femoral and mandibular bone density and on induced periodontal disease,” Journal of Periodontology, vol. 78, no. 1, pp. 164–169, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. G. Jonasson, G. Bankvall, and S. Kiliaridis, “Estimation of skeletal bone mineral density by means of the trabecular pattern of the alveolar bone, its interdental thickness, and the bone mass of the mandible,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 92, no. 3, pp. 346–352, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. Naitoh, Y. Kurosu, K. Inagaki, A. Katsumata, T. Noguchi, and E. Ariji, “Assessment of mandibular buccal and lingual cortical bones in postmenopausal women,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 104, no. 4, pp. 545–550, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. P. D. Allen, J. Graham, D. J. J. Farnell et al., “Detecting reduced bone mineral density from dental radiographs using statistical shape models,” IEEE Transactions on Information Technology in Biomedicine, vol. 11, no. 6, pp. 601–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Z. Vlasiadis, J. Damilakis, G. A. Velegrakis et al., “Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis,” Maturitas, vol. 59, no. 3, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. B. Çakur, A. Şahin, S. Dagistan et al., “Dental panoramic radiography in the diagnosis of osteoporosis,” Journal of International Medical Research, vol. 36, no. 4, pp. 792–799, 2008. View at Google Scholar · View at Scopus
  49. H. Devlin, P. D. Allen, J. Graham et al., “Automated osteoporosis risk assessment by dentists: a new pathway to diagnosis,” Bone, vol. 40, no. 4, pp. 835–842, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. K. Ishii, A. Taguchi, T. Nakamoto et al., “Diagnostic efficacy of alveolar bone loss of the mandible for identifying postmenopausal women with femoral osteoporosis,” Dentomaxillofacial Radiology, vol. 36, no. 1, pp. 28–33, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. H. Devlin, K. Karayianni, A. Mitsea et al., “Diagnosing osteoporosis by using dental panoramic radiographs: the OSTEODENT project,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 104, no. 6, pp. 821–828, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. K. Horner, K. Karayianni, A. Mitsea et al., “The mandibular cortex on radiographs as a tool for osteoporosis risk assessment: the OSTEODENT project,” Journal of Clinical Densitometry, vol. 10, no. 2, pp. 138–146, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. W. G. M. Geraets, J. G. C. Verheij, P. F. van der Stelt et al., “Prediction of bone mineral density with dental radiographs,” Bone, vol. 40, no. 5, pp. 1217–1221, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. K. Nicopoulou-Karayianni, P. Tzoutzoukos, A. Mitsea et al., “Tooth loss and osteoporosis: the osteodent study,” Journal of Clinical Periodontology, vol. 36, no. 3, pp. 190–197, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. K. Horner, P. Allen, J. Graham et al., “The relationship between the OSTEODENT index and hip fracture risk assessment using FRAX,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 110, no. 2, pp. 243–249, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. K. Karayianni, K. Horner, A. Mitsea et al., “Accuracy in osteoporosis diagnosis of a combination of mandibular cortical width measurement on dental panoramic radiographs and a clinical risk index (OSIRIS): the OSTEODENT project,” Bone, vol. 40, no. 1, pp. 223–229, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. C. Lindh, K. Horner, G. Jonasson et al., “The use of visual assessment of dental radiographs for identifying women at risk of having osteoporosis: the OSTEODENT project,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 106, no. 2, pp. 285–293, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. H. Devlin H., P. Allen, J. Graham et al., “The role of the dental surgeon in detecting osteoporosis: the OSTEODENT study,” British Dental Journal, vol. 204, no. 10, p. E16, 2008, discussion 560-561. View at Google Scholar
  59. A. Kyrgidis, S. Triaridis, K. Vahtsevanos, and K. Antoniades, “Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients,” Expert Review of Anticancer Therapy, vol. 9, no. 8, pp. 1125–1134, 2009. View at Publisher · View at Google Scholar · View at PubMed
  60. R. E. Coleman, “Risks and benefits of bisphosphonates,” British Journal of Cancer, vol. 98, no. 11, pp. 1736–1740, 2008. View at Publisher · View at Google Scholar · View at PubMed
  61. J. V. Bagan, Y. Jimenez, J. M. Diaz et al., “Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification,” Oral Oncology, vol. 45, no. 7, pp. 645–646, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, “American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update,” Journal of Oral and Maxillofacial Surgery, vol. 67, supplement 5, pp. 2–12, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Kyrgidis, ST. Triaridis, and K. Vahtsevanos, “New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment,” Hippokratia, vol. 13, no. 1, p. 64, 2009. View at Google Scholar
  64. G. Colella, G. Campisi, and V. Fusco, “American association of oral and maxillofacial surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 12, pp. 2698–2699, 2009. View at Publisher · View at Google Scholar · View at PubMed
  65. L. M. Hess, J. M. Jeter, M. Benham-Hutchins, and D. S. Alberts, “Factors associated with osteonecrosis of the jaw among bisphosphonate users,” American Journal of Medicine, vol. 121, no. 6, pp. 475–e3, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. M. Pazianas, C. Cooper, F. H. Ebetino, and R. G. G. Russell, “Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis,” Therapeutics and Clinical Risk Management, vol. 6, pp. 325–343, 2010. View at Google Scholar
  67. M. Pazianas, P. Miller, W. A. Blumentals, M. Bernal, and P. Kothawala, “A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics,” Clinical Therapeutics, vol. 29, no. 8, pp. 1548–1558, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. Kyrgidis, K. Vahtsevanos, G. Koloutsos et al., “Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4634–4638, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. K. Vahtsevanos, A. Kyrgidis, E. Verrou et al., “Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5356–5362, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. A. O. Hoff, B. B. Toth, K. Altundag et al., “Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates,” Journal of Bone and Mineral Research, vol. 23, no. 6, pp. 826–836, 2008. View at Publisher · View at Google Scholar · View at PubMed
  71. C. L. Estilo, C. H. Van Poznak, T. Wiliams et al., “Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy,” Oncologist, vol. 13, no. 8, pp. 911–920, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. A. Kyrgidis and K. Vahtsevanos, “A safe modality,” British Dental Journal, vol. 206, no. 11, pp. 561–562, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. K. Zervas, E. Verrou, Z. Teleioudis et al., “Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients,” British Journal of Haematology, vol. 134, no. 6, pp. 620–623, 2006. View at Publisher · View at Google Scholar · View at PubMed
  74. S. B. Woo, J. W. Hellstein, and J. R. Kalmar, “Systematic review: bisphosphonates and osteonecrosis of the jaws,” Annals of Internal Medicine, vol. 144, no. 10, pp. 753–761, 2006. View at Google Scholar
  75. A. Kyrgidis and S. Triaridis, “Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding ‘risks and benefits of bisphosphonates’,” British Journal of Cancer, vol. 100, no. 4, p. 670, 2009. View at Publisher · View at Google Scholar · View at PubMed
  76. G. Lodi, A. Sardella, A. Salis, F. Demarosi, M. Tarozzi, and A. Carrassi, “Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series,” Journal of Oral and Maxillofacial Surgery, vol. 68, no. 1, pp. 107–110, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. J. V. Bagan, Y. Jimenez, J. M. Diaz et al., “Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification,” Oral Oncology, vol. 45, no. 7, pp. 645–646, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. A. Wutzl, E. Biedermann, F. Wanschitz et al., “Treatment results of bisphosphonate-related osteonecrosis of the jaws,” Head and Neck, vol. 30, no. 9, pp. 1224–1230, 2008. View at Publisher · View at Google Scholar · View at PubMed
  79. A. Kyrgidis, S. Triaridis, and K. Antoniades, “Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw,” Bioscience Hypotheses, vol. 2, no. 3, pp. 153–159, 2009. View at Publisher · View at Google Scholar
  80. J.-H. Lenz, B. Steiner-Krammer, W. Schmidt, R. Fietkau, P. C. Mueller, and K. K.H. Gundlach, “Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?” Journal of Cranio-Maxillofacial Surgery, vol. 33, no. 6, pp. 395–403, 2005. View at Publisher · View at Google Scholar · View at PubMed
  81. C. Pautke, F. Bauer, T. Tischer et al., “Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 3, pp. 471–476, 2009. View at Publisher · View at Google Scholar · View at PubMed
  82. C. Pautke, F. Bauer, O. Bissinger et al., “Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy,” Journal of Oral and Maxillofacial Surgery, vol. 68, no. 1, pp. 125–129, 2010. View at Publisher · View at Google Scholar · View at PubMed
  83. A. Kyrgidis and K. Vahtsevanos, “"Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws,” Clinical Oral Investigations, vol. 13, no. 4, pp. 479–480, 2009. View at Publisher · View at Google Scholar · View at PubMed
  84. M. R. Allen and D. B. Burr, “The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 61–70, 2009. View at Publisher · View at Google Scholar · View at PubMed
  85. A. Kyrgidis and E. Verrou, “Fatigue in bone: a novel phenomenon attributable to bisphosphonate use,” Bone, vol. 46, no. 2, p. 556, 2010. View at Publisher · View at Google Scholar · View at PubMed
  86. C. Magopoulos, G. Karakinaris, Z. Telioudis et al., “Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals,” American Journal of Otolaryngology, vol. 28, no. 3, pp. 158–163, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. M. Kos and K. Luczak, “Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation,” Bioscience Hypotheses, vol. 2, no. 1, pp. 34–36, 2009. View at Publisher · View at Google Scholar
  88. A. Kyrgidis and K. A. Toulis, “Denosumab-related osteonecrosis of the jaws,” Osteoporosis International, vol. 22, no. 1, pp. 369–370, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. K. Thompson, A. J. Roelofs, M. Jauhiainen, H. Mönkkönen, J. Mönkkönen, and M. J. Rogers, “Activation of γδ T cells by bisphosphonates,” Advances in Experimental Medicine and Biology, vol. 658, pp. 11–20, 2010. View at Google Scholar
  90. M. Pazianas, “Osteonecrosis of the jaw and the role of macrophages,” The Journal of the National Cancer Institute, vol. 103, pp. 232–240, 2011. View at Publisher · View at Google Scholar · View at PubMed
  91. R. E. Marx, Y. Sawatari, M. Fortin, and V. Broumand, “Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 63, no. 11, pp. 1567–1575, 2005. View at Publisher · View at Google Scholar · View at PubMed
  92. A. Kyrgidis, G. Koloutsos, and K. Vahtsevanos, “Treatment protocols of bisphosphonate-related osteonecrosis of the jaws,” Head and Neck, vol. 31, no. 8, pp. 1112–1113, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. D. M. Black, A. V. Schwartz, K. E. Ensrud et al., “Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial,” Journal of the American Medical Association, vol. 296, no. 24, pp. 2927–2938, 2006. View at Publisher · View at Google Scholar · View at PubMed
  94. C. L. Leibson, A. N. A. Tosteson, S. E. Gabriel, J. E. Ransom, and L. J. Melton, “Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study,” Journal of the American Geriatrics Society, vol. 50, no. 10, pp. 1644–1650, 2002. View at Publisher · View at Google Scholar
  95. C. A. Migliorati, J. Casiglia, J. Epstein, P. L. Jacobsem, M. A. Siegel, and S. B. Woo, “Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper,” Journal of the American Dental Association, vol. 136, no. 12, pp. 1658–1668, 2005. View at Google Scholar
  96. S. Ruggiero, J. Gralow, R. E. Marx et al., “Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jawsin patients with cancer,” Journal of Oncology Practice, vol. 2, no. 1, pp. 7–14, 2006. View at Google Scholar
  97. N. Yarom, R. Yahalom, Y. Shoshani, W. Hamed, E. Regev, and S. Elad, “Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome,” Osteoporosis International, vol. 18, no. 10, pp. 1363–1370, 2007. View at Publisher · View at Google Scholar · View at PubMed
  98. R. E. Marx, J. E. Cillo, and J. J. Ulloa, “Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 12, pp. 2397–2410, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. S. Khosla, “Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 66, no. 6, pp. 1320–1321, 2008, author reply 1-2. View at Publisher · View at Google Scholar · View at PubMed
  100. C. Y. S. Lee and J. B. Suzuki, “CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature,” Implant Dentistry, vol. 18, no. 6, pp. 492–500, 2009. View at Publisher · View at Google Scholar · View at PubMed
  101. C. Y. S. Lee and J. B. Suzuki, “CTX biochemical marker of bone metabolism. is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study,” Implant Dentistry, vol. 19, no. 1, pp. 29–38, 2010. View at Publisher · View at Google Scholar · View at PubMed
  102. S. Khosla, D. Burr, J. Cauley et al., “Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research, vol. 22, no. 10, pp. 1479–1491, 2007. View at Publisher · View at Google Scholar · View at PubMed
  103. A. Cheng, A. Mavrokokki, G. Carter et al., “The dental implications of bisphosphonates and bone disease,” Australian Dental Journal, vol. 50, no. 4, pp. S4–S13, 2005. View at Google Scholar
  104. J. T. Grbic, D. M. Black, K. W. Lyles et al., “The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program,” Journal of the American Dental Association, vol. 141, no. 11, pp. 1365–1370, 2010. View at Google Scholar
  105. “FDA approves new injectable osteoporosis treatment for postmenopausal women,” http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm214150.htm.
  106. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at PubMed
  107. A. Kyrgidis, “Denosumab, osteoporosis, and prevention of fractures,” The New England Journal of Medicine, vol. 361, no. 22, p. 2189, 2009. View at Google Scholar
  108. “FDA approves Xgeva to help prevent cancer-related bone injury,” http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm.
  109. A. Grey, “Teriparatide for bone loss in the jaw,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2458–2459, 2010. View at Publisher · View at Google Scholar · View at PubMed
  110. J. D. Bashutski, R. M. Eber, J. S. Kinney et al., “Teriparatide and osseous regeneration in the oral cavity,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2396–2405, 2010. View at Publisher · View at Google Scholar · View at PubMed
  111. R. P. Harper and E. Fung, “Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1–34)],” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 3, pp. 573–580, 2007. View at Publisher · View at Google Scholar · View at PubMed
  112. A. Cheung and E. Seeman, “Teriparatide therapy for alendronate-associated osteonecrosis of the jaw,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2473–2474, 2010. View at Publisher · View at Google Scholar · View at PubMed
  113. A. Kyrgidis and K. Antoniades, “Could teriparatide be the treatment for osteonecrosis of the jaws?” Head & Neck. In press. View at Publisher · View at Google Scholar · View at PubMed
  114. J.-J. Lee, S.-J. Cheng, J.-H. Jeng et al., “Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy,” Head & Neck. In press. View at Publisher · View at Google Scholar · View at PubMed